Tags

Type your tag names separated by a space and hit enter

National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011.
MMWR Morb Mortal Wkly Rep. 2012 Aug 31; 61(34):671-7.MM

Abstract

Since 2005, the Advisory Committee on Immunization Practices (ACIP) has expanded the routine adolescent vaccination schedule with administration of the following vaccines at ages 11 or 12 years: meningococcal conjugate (MenACWY), 2 doses; tetanus, diphtheria, acellular pertussis (Tdap), 1 dose; human papillomavirus (HPV), 3 doses; and influenza, 1 dose annually. To assess vaccination coverage among adolescents aged 13-17 years, CDC analyzed data from the National Immunization Survey-Teen (NIS-Teen). This report summarizes the results of that assessment, which indicated that, from 2010 to 2011, vaccination coverage increased for ≥1 dose Tdap on or after age 10 years (from 68.7% to 78.2%), ≥1 dose MenACWY (from 62.7% to 70.5%), and, among females, for ≥1 dose of HPV (from 48.7% to 53.0%) and ≥3 doses of HPV (from 32.0 to 34.8%). Vaccination coverage varied widely among states. Interventions that increase adolescent vaccination coverage include strong recommendations from health-care providers, urging consideration of every health visit as an opportunity for vaccination, reducing out-of-pocket costs, and using reminder/recall systems. Despite increasing adolescent vaccination coverage, the percentage point increase in ≥1 dose HPV coverage among adolescent females was less than half that of the increase in ≥1 dose of Tdap or MenACWY. The causes of lower coverage with HPV vaccine are multifactorial; addressing missed opportunities for vaccination, as well as continued evaluation of vaccination-promoting initiatives, is needed to protect adolescents against HPV-related cancers.

Authors

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22932301

Citation

Centers for Disease Control and Prevention (CDC). "National and State Vaccination Coverage Among Adolescents Aged 13-17 years--United States, 2011." MMWR. Morbidity and Mortality Weekly Report, vol. 61, no. 34, 2012, pp. 671-7.
Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(34):671-7.
Centers for Disease Control and Prevention (CDC). (2012). National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011. MMWR. Morbidity and Mortality Weekly Report, 61(34), 671-7.
Centers for Disease Control and Prevention (CDC). National and State Vaccination Coverage Among Adolescents Aged 13-17 years--United States, 2011. MMWR Morb Mortal Wkly Rep. 2012 Aug 31;61(34):671-7. PubMed PMID: 22932301.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011. A1 - ,, PY - 2012/8/31/entrez PY - 2012/8/31/pubmed PY - 2012/10/26/medline SP - 671 EP - 7 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 61 IS - 34 N2 - Since 2005, the Advisory Committee on Immunization Practices (ACIP) has expanded the routine adolescent vaccination schedule with administration of the following vaccines at ages 11 or 12 years: meningococcal conjugate (MenACWY), 2 doses; tetanus, diphtheria, acellular pertussis (Tdap), 1 dose; human papillomavirus (HPV), 3 doses; and influenza, 1 dose annually. To assess vaccination coverage among adolescents aged 13-17 years, CDC analyzed data from the National Immunization Survey-Teen (NIS-Teen). This report summarizes the results of that assessment, which indicated that, from 2010 to 2011, vaccination coverage increased for ≥1 dose Tdap on or after age 10 years (from 68.7% to 78.2%), ≥1 dose MenACWY (from 62.7% to 70.5%), and, among females, for ≥1 dose of HPV (from 48.7% to 53.0%) and ≥3 doses of HPV (from 32.0 to 34.8%). Vaccination coverage varied widely among states. Interventions that increase adolescent vaccination coverage include strong recommendations from health-care providers, urging consideration of every health visit as an opportunity for vaccination, reducing out-of-pocket costs, and using reminder/recall systems. Despite increasing adolescent vaccination coverage, the percentage point increase in ≥1 dose HPV coverage among adolescent females was less than half that of the increase in ≥1 dose of Tdap or MenACWY. The causes of lower coverage with HPV vaccine are multifactorial; addressing missed opportunities for vaccination, as well as continued evaluation of vaccination-promoting initiatives, is needed to protect adolescents against HPV-related cancers. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/22932301/National_and_state_vaccination_coverage_among_adolescents_aged_13_17_years__United_States_2011_ L2 - https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6134a3.htm DB - PRIME DP - Unbound Medicine ER -